Erythema Migrans

Infectious Disease Clinics of North America

Volumn 22, Issue 2, 2008, Pages 235-260

  Dandache, Patricia ^a   Nadelman, Robert B ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME AXETIL; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; PENICILLIN G; PENICILLIN V; PROBENECID; TETRACYCLINE;

ABORTION; ADD ON THERAPY; ANTIMICROBIAL THERAPY; BACTERIAL STRAIN; BORRELIA BURGDORFERI; CELLULITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONTACT DERMATITIS; DIAGNOSTIC TEST; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG TOLERABILITY; ERYTHEMA CHRONICUM MIGRANS; ESOPHAGITIS; EVOLUTION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; LABORATORY DIAGNOSIS; LYME DISEASE; PHOTOSENSITIVITY; PREGNANCY OUTCOME; PREMATURE LABOR; RASH; RECURRENT DISEASE; REINFECTION; REVIEW; SINGLE DRUG DOSE; SKIN DISEASE; SPIDER BITE; SPIROCHETE; SYMPTOM; SYNDACTYLY; TICK BITE; TINEA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE; URTICARIA; VACCINATION;

ANIMALS; ARACHNID VECTORS; BITES AND STINGS; DIAGNOSIS, DIFFERENTIAL; ERYTHEMA CHRONICUM MIGRANS; HISTORY, 20TH CENTURY; HUMANS; TICKS;

EID: 42949108595     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2007.12.012     Document Type: Review

References (104)

1. Nadelman R.B., and Wormser G.P. Recognition and treatment of erythema migrans: are we off target. Ann Intern Med 136 6 (2002) 477-479
2. Nadelman R.B., and Wormser G.P. Lyme borreliosis. Lancet 352 9127 (1998) 557-565
3. Gerber M.A., Shapiro E.D., Burke G.S., et al. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. N Engl J Med 335 17 (1996) 1270-1274
4. Krause P.J., Telford III S.R., Spielman A., et al. Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness. JAMA 275 21 (1996) 1657-1660
5. Nadelman R.B., and Wormser G.P. Erythema migrans and early Lyme disease. Am J Med 98 4A (1995) 15S-23S
6. Steere A.C., Snydman D., Murray P., et al. Historical perspectives. In: Stanek G., Flamm H., Barbour A.G., et al. (Eds). Lyme borreliosis. Proceedings of the 2nd International Symposium on Lyme Disease and Related Disorders (1987), Gustav Fischer Verlag, New York 3-6
7. Åsbrink E., and Olsson I. Clinical manifestations of erythema chronicum migrans afzelius in 161 patients. Acta Derm Venereol 65 1 (1985) 43-52
8. Steere A.C., Bartenhagen N.H., Craft J.E., et al. The early clinical manifestations of Lyme disease. Ann Intern Med 99 1 (1983) 76-82
9. Hollström E. Successful treatment of erythema migrans afzelius. Acta Derm Venereol 31 2 (1951) 235-243
10. Berger B.W. Dermatologic manifestations of Lyme disease. Rev Infect Dis 11 Suppl 6 (1989) S1475-S1481
11. Nadelman R.B., Nowakowski J., Forseter G., et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med 100 5 (1996) 502-508
12. Malane M.S., Grant-Kels J.M., Feder H.M., et al. Diagnosis of Lyme disease based on dermatologic manifestations. Ann Intern Med 114 6 (1991) 490-498
13. Centers for Disease Control and Prevention (CDC). Lyme disease-United States 2003-2005. MMWR Morb Mortal Wkly Rep 56 (2007) 573-576
14. Wormser G.P. Early Lyme disease. N Engl J Med 354 (2006) 2794-2801
15. Wormser G.P., Dattwyler R.J., Shapiro E.D., et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43 9 (2006) 1089-1134 Erratum in: Clin Infect Dis 2007;45(7):941
16. Feder H.M., and Whitaker D.L. Misdiagnosis of erythema migrans. Am J Med 99 4 (1995) 412-419
17. Smith R.P., Schoen R.T., Rahn D.W., et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med 136 6 (2002) 421-428
18. Nadelman R.B., Nowakowski J., Fish D., et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 345 2 (2001) 79-84
19. Tibbles C.D., and Edlow J.A. Does this patient have erythema migrans?. JAMA 297 23 (2007) 2617-2627
20. Ribeiro J.M., Mather T.N., Piesman J., et al. Dissemination and salivary delivery of Lyme disease spirochetes in vector ticks. J Med Entomol 24 2 (1987) 201-205
21. Habif T.P. Infestations and bites. Clinical dermatology. 4th edition (2004), Mosby Inc., St. Louis (MO) 497-546
22. Melski J.W., Reed K.D., Mitchell P.D., et al. Primary and secondary erythema migrans in central Wisconsin. Arch Dermatol 129 6 (1993) 709-716
23. Nadelman R.B., and Wormser G.P. Reinfection in patients with Lyme disease. Clin Infect Dis 45 8 (2007) 1032-1038
24. Nowakowski J., Nadelman R.B., Sell R., et al. Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med 115 2 (2003) 91-96
25. Strle F., Nadelman R.B., Cimperman J., et al. Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York and by Borrelia afzelii in Slovenia. Ann Intern Med 130 1 (1999) 32-36
26. Berger B.W., Johnson R.C., Kodner C., et al. Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin. J Clin Microbiol 30 2 (1992) 359-361
27. Jurca T., Ruzic-Sabljic E., Lotric-Furlan S., et al. Comparison of peripheral and central biopsy sites for the isolation of Borrelia burgdorferi sensu lato from erythema migrans skin lesions. Clin Infect Dis 27 3 (1998) 636-638
28. Kuiper H., Cairo I., Van Dam A., et al. Solitary erythema migrans: a clinical, laboratory and epidemiological study of 77 Dutch patients. Br J Dermatol 130 4 (1994) 466-472
29. Lipsker D., Antoni-Bach N., Hansmann Y., et al. Long-term prognosis of patients treated for erythema migrans in France. Br J Dermatol 146 5 (2002) 872-876
30. Logar M., Ruzic-Sabljic E., Maraspin V., et al. Comparison of erythema migrans caused by Borrelia afzelii and Borrelia garinii. Infection 32 1 (2004) 15-19
31. Goldberg N.S., Forseter G., Nadelman R.B., et al. Vesicular erythema migrans. Arch Dermatol 128 11 (1992) 1495-1498
32. Strle F., Nelson J.A., Ruzic-Sabljic E., et al. European Lyme borreliosis: 231 culture-confirmed cases involving patients with erythema migrans. Clin Infect Dis 23 1 (1996) 61-65
33. Weber K., Preac-Mursic V., Neubert U., et al. Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans. Ann N Y Acad Sci 539 (1988) 324-345
34. Weber K., Preac-Mursic V., Wilske B., et al. A randomized trial of ceftriaxone versus oral penicillin for the treatment of early European Lyme borreliosis. Infection 18 2 (1990) 91-96
35. Wormser G.P., McKenna D., Carlin J., et al. Brief communication: hematogenous dissemination in early Lyme disease. Ann Intern Med 142 9 (2005) 751-755
36. Liveris D., Varde S., Iyer R., et al. Genetic diversity of Borrelia burgdorferi in Lyme disease patients as determined by culture versus direct PCR with clinical specimens. J Clin Microbiol 37 3 (1999) 565-569
37. Seinost G., Dykhuizen D.E., Dattwyler R.J., et al. Four clones of Borrelia burgdorferi sensu stricto cause invasive infections in humans. Infect Immun 67 7 (1999) 3518-3524
38. Grimm D., Tilly K., Byram R., et al. Outer surface protein C of the Lyme disease spirochete: a protein induced in ticks for infection in mammals. Proc Natl Acad Sci U S A 101 9 (2004) 3142-3147
39. Steere A.C., Schoen R.T., Taylor E., et al. The clinical evolution of Lyme arthritis. Ann Intern Med 107 5 (1987) 725-731
40. Aguero-Rosenfeld M.E., Nowakowski J., McKenna D., et al. Serodiagnosis in early Lyme disease. J Clin Microbiol 31 12 (1993) 3090-3095
41. Aguero-Rosenfeld M.E., Wang G., Schwartz I., et al. Diagnosis of Lyme borreliosis. Clin Microbiol Rev 18 3 (2005) 484-509
42. Falco R.C., McKenna D.F., Daniels T.J., et al. Temporal relation between Ixodes scapularis abundance and risk for Lyme disease associated with erythema migrans. Am J Epidemiol 149 8 (1999) 771-776
43. Krause P.J., Foley D.T., Burke G.S., et al. Reinfection and relapse in early Lyme disease. Am J Trop Med Hyg 75 6 (2006) 1090-1094
44. Fish D. Environmental risk and prevention of Lyme disease. Am J Med 98 4A (1995) 2S-8S
45. Hashimoto Y., Kawagishi N., Sakai H., et al. Lyme disease in Japan. Analysis of Borrelia species using rRNA gene restriction fragment length polymorphism. Dermatology 191 3 (1995) 193-198
46. Busch U., Hizo-Teufel C., Böhmer R., et al. Borrelia burgdorferi sensu lato strains isolated from cutaneous Lyme borreliosis biopsies differentiated by pulsed-field gel electrophoresis. Scand J Infect Dis 28 6 (1996) 583-589
47. Ornstein K., Berglund J., Nilsson I., et al. Characterization of Lyme borreliosis isolates from patients with erythema migrans and neuroborreliosis in southern Sweden. J Clin Microbiol 39 4 (2001) 1294-1298
48. Masuzawa T. Terrestrial distribution of the Lyme borreliosis agent Borrelia burgdorferi sensu lato in East Asia. Jpn J Infect Dis 57 6 (2004) 229-235
49. Nadelman R.B., Horowitz H.W., Hsieh T.-C., et al. Simultaneous human ehrlichiosis and Lyme borreliosis. N Engl J Med 337 1 (1997) 27-30
50. Rubin D.A., Sorbera C., Nikitin P., et al. Prospective evaluation of heart block complicating early Lyme disease. Pacing Clin Electrophysiol 15 3 (1992) 252-255
51. Haddad F.A., and Nadelman R.B. Lyme disease and the heart. Front Biosci 8 (2003) s769-s782
52. Frithsen I.L., Vetter R.S., and Stocks I.C. Reports of envenomation by brown recluse spiders exceed verified specimens of Loxosceles spiders in South Carolina. J Am Board Fam Med 20 5 (2007) 483-488
53. Vetter R.S., and Bush S.P. Reports of presumptive brown recluse spider bites reinforce improbable diagnosis in regions of North America where the spider is not endemic. Clin Infect Dis 35 4 (2002) 442-445
54. Masters E., Granter S., Duray P., et al. Physician-diagnosed erythema migrans and erythema migrans-like rashes following Lone Star tick bites. Arch Dermatol 134 8 (1998) 955-960
55. Kirkland K.B., Klimko T.B., Meriwether R.A., et al. Erythema migrans-like rash illness at a camp in North Carolina: a new tick-borne disease?. Arch Intern Med 157 22 (1997) 2635-2641
56. Wormser G.P., Masters E., Nowakowski J., et al. Prospective clinical evaluation of patients from Missouri and New York with erythema migrans-like skin lesions. Clin Infect Dis 41 7 (2005) 958-965
57. Wormser G.P., Masters E., Liveris D., et al. Microbiologic evaluation of patients from Missouri with erythema migrans. Clin Infect Dis 40 3 (2005) 423-428
58. Felz M.W., Durden L.A., and Oliver Jr. J.H. Ticks parasitizing humans in Georgia and South Carolina. J Parasitol 82 3 (1996) 505-508
59. Piesman J., and Sinsky R.J. Ability of Ixodes scapularis, Dermacentor variabilis and Amblyomma americanum to acquire, maintain and transmit Lyme disease spirochetes. J Med Entomol 25 (1988) 336-339
60. Barbour A.G., Maupin G.O., Teltow G.J., et al. Identification of an uncultivable Borrelia species in the hard tick Amblyomma americanum: possible agent of a Lyme disease-like illness. J Med Entomol 25 5 (1988) 336-339
61. Steere A.C., McHugh G., Suarez C., et al. Prospective study of coinfection in patients with erythema migrans. Clin Infect Dis 36 8 (2003) 1078-1081
62. Belongia E.A., Reed K.D., Mitchell P.D., et al. Clinical and epidemiological features of early Lyme disease and human granulocytic ehrlichiosis in Wisconsin. Clin Infect Dis 29 6 (1999) 1472-1477
63. Nadelman R.B., Nowakowski J., Horowitz H.W., et al. Thrombocytopenia and Borrelia burgdorferi: an association remains unproven. Clin Infect Dis 29 6 (1999) 1603-1605
64. Nowakowski J., Schwartz I., Liveris D., et al. Laboratory diagnostic techniques for patients with early Lyme disease associated with erythema migrans: a comparison of different techniques. Clin Infect Dis 33 12 (2001) 2023-2027
65. Centers for Disease Control and Prevention (CDC). Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 44 (1995) 590-591
66. Steere A.C., Hutchinson G.J., Rahn D.W., et al. Treatment of the early manifestations of Lyme disease. Ann Intern Med 99 1 (1983) 22-26
67. Dattwyler R.J., Volkman D.J., Conaty S.M., et al. Amoxicillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet 336 8728 (1990) 1404-1406
68. Massarotti E.M., Luger S.W., Rahn D.W., et al. Treatment of early Lyme disease. Am J Med 92 4 (1992) 396-403
69. Nadelman R.B., Luger S.W., Frank E., et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 117 4 (1992) 273-280
70. Luger S.W., Paparone P., Wormser G.P., et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 39 3 (1995) 661-667
71. Dattwyler R.J., Luft B.J., Kunkel M.J., et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med 337 5 (1997) 289-294
72. Luft B.J., Dattwyler R.J., Johnson R., et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double blind, randomized, controlled trial. Ann Intern Med 124 9 (1996) 785-791
73. Weber K., Wilske B., Preac-Mursic V., et al. Azithromycin versus penicillin V for the treatment of early Lyme borreliosis. Infection 21 6 (1993) 367-372
74. Strle F., Ruzic E., and Cimperman J. Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin. J Antimicrob Chemother 30 4 (1992) 543-550
75. Strle F., Maraspin V., Lotric-Furlan S., et al. Azithromycin and doxycycline for treatment of Borrelia culture-proven erythema migrans. Infection 24 1 (1996) 64-68
76. Hansen K., Hovmark A., Lebech A.M., et al. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm Venereol 72 4 (1992) 297-300
77. Wormser G.P., Ramanathan R., Nowakowski J., et al. Duration of antibiotic therapy for early Lyme disease. Ann Intern Med 138 9 (2003) 697-704
78. Eppes S.C., and Childs J.A. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics 109 6 (2002) 1173-1177
79. Nowakowski J., McKenna D., Nadelman R.B., et al. Failure of treatment with cephalexin for Lyme disease. Arch Fam Med 9 6 (2000) 563-567
80. Steere A.C., Sikand V.K., Meurice F., et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med 339 4 (1998) 209-215
81. Hulshof M.M., Vandenbroucke J.P., Nohlmans L.M., et al. Long-term prognosis in patients treated for erythema chronicum migrans and acrodermatitis chronica atrophicans. Arch Dermatol 133 1 (1997) 33-37
82. Feder Jr. H.M., Johnson B.J., O'Connell S., et al. A critical appraisal of "chronic Lyme disease.". N Engl J Med 357 14 (2007) 1422-1430
83. Nadelman R.B., Arlin Z., Wormser G.P., et al. Life-threatening complications of empiric ceftriaxone therapy for 'seronegative Lyme disease'. South Med J 84 10 (1991) 1263-1265
84. Fallon B.A., Keilp J.G., Corbera K.M., et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology (2007) [Epub ahead of print]
85. Klempner M.S., Hu L.T., Evans J., et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 345 2 (2001) 85-92
86. Krupp L.B., Hyman L.G., Grimson R., et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 60 12 (2003) 1923-1930
87. Ettestad P.J., Campbell G.L., Welbel S.F., et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis 171 2 (1995) 356-361
88. Patel R., Grogg K.L., Edwards W.D., et al. Death from inappropriate therapy for Lyme disease. Clin Infect Dis 31 4 (2000) 1107-1109
89. Halperin J.J. Prolonged Lyme disease treatment. Neurology (2007) [Epub ahead of print]
90. Barsky A.J., and Borus J.F. Functional somatic syndromes. Ann Intern Med 130 11 (1999) 910-921
91. Seltzer E.G., Gerber M.A., Cartter M.L., et al. Long-term outcomes of persons with Lyme disease. JAMA 283 5 (2000) 609-616
92. Markowitz L.E., Steere A.C., Benach J.L., et al. Lyme disease during pregnancy. JAMA 255 24 (1986) 3394-3396
93. Williams C.L., Strobino B., Weinstein A., et al. Maternal Lyme disease and congenital malformation: a cord blood serosurvey in endemic and control areas. Paediatr Perinat Epidemiol 9 3 (1995) 320-330
94. Strobino B., Abid S., and Gewitz M. Maternal Lyme disease and congenital heart disease: a case-control study in an endemic area. Am J Obstet Gynecol 180 3 Pt 1 (1999) 711-716
95. Strobino B.A., Williams C.L., Abid S., et al. Lyme disease and pregnancy outcome: a prospective study of two thousand prenatal patients. Am J Obstet Gynecol 169 2 Pt 1 (1993) 367-374
96. Gerber M.A., and Zalneraitis E.L. Childhood neurologic disorders and Lyme disease during pregnancy. Pediatr Neurol 11 1 (1994) 41-43
97. Maraspin V., Cimperman J., Lotric-Furlan S., et al. Erythema migrans in pregnancy. Wien Klin Wochenschr 111 22-23 (1999) 933-940
98. Maraspin V., Cimperman J., Lotric-Furlan S., et al. Erythema migrans in solid organ transplant recipients. Clin Infect Dis 42 12 (2006) 1751-1754
99. Fürst B., Glatz M., Kerl H., et al. The impact of immunosuppression on erythema migrans. A retrospective study of clinical presentation, response to treatment and production of Borrelia antibodies in 33 patients. Clin Exp Dermatol 31 4 (2006) 509-514 Erratum in: Clin Exp Dermatol. 2006;31(5):751
100. Maraspin V., Lotric-Furlan S., Cimperman J., et al. Erythema migrans in the immunocompromised host. Wien Klin Wochenschr 111 22-23 (1990) 923-932
101. Nadelman RB, Hanincova K, Madison G, et al. Outer surface protein C (OspC) genotypes in patients with infection and reinfection with Borrelia burgdorferi. Presented at the 45th meeting of the Infectious Diseases Society of America. San Diego, CA, October 4-7, 2007. Abstract 667, p. 67.
102. Probert W.S., Crawford M., Cadiz R.B., et al. Immunization with outer surface protein (Osp)A but not OspC provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi. J Infect Dis 175 2 (1997) 400-405
103. Nadelman RB, Gaidici AT, McKenna D, et al. Comparison of clinical manifestations of 1st and 2nd episodes of erythema migrans (EM). In: Program and abstracts of the 9th International Conference on Lyme Borreliosis and Other Tick-Borne Diseases. New York, 2002. Abstract P-51.
104. Hayes E.B., and Piesman J. How can we prevent Lyme disease?. N Engl J Med 348 24 (2003) 2424-2430